AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24558011 — intervention group
Group type: COMPARATOR
Intervention: Tablet (paracetamol)
Number of subjects: 25
Study 22721545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 1 g loading dose followed by 1 g maintenance dose over 8 hours
Number of subjects: 10000
Study 22721545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study 19541477 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of sexual dysfunction (measured by self-completed questionnaire)
Number of subjects: 8924
Study 17227744 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic combination medication
Number of subjects: 60
Study 17227744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15943961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytrex bid (twice a day)
Number of subjects: 0
Study 15943961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytrex bid
Number of subjects: 0
Study 15943961 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone qid
Number of subjects: 0
Study 15943961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12213107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg day(-1))
Number of subjects: 10
Study 12213107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9796240 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated epidural/general anaesthesia
Number of subjects: 1200
Study 9796240 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic volume preload
Number of subjects: 1200
Study 9796240 — intervention group
Group type: COMPARATOR
Intervention: Epidural clonidine
Number of subjects: 1200
Study 9796240 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic atropine before epidural block
Number of subjects: 1200
Study 7704460 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow‐acting anti‐rheumatic drugs (SAARD)
Number of subjects: 115
Study 2696292 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Felbinac gel (1 or 2 g)
Number of subjects: 30
Study 2696292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Fenbufen (300 mg thrice daily)
Number of subjects: 30
Study 2696292 — intervention group
Group type: COMPARATOR
Intervention: Topical administration (Felbinac gel)
Number of subjects: 30
Study 2696292 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tissue concentrations after topical administration
Number of subjects: 30
Study 773080 — intervention group
Group type: EXPERIMENTAL
Intervention: CB 154 (2-bromo-alpha-ergocryptine)
Number of subjects: 20
Study 773080 — intervention group
Group type: COMPARATOR
Intervention: Madopar (L-Dopa + benserazid)
Number of subjects: 20
Study 30779528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation
Number of subjects: 401
Study 30779528 — intervention group
Group type: COMPARATOR
Intervention: No ventilation
Number of subjects: 401
Study 28120127 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-8539 (450 mg)
Number of subjects: 20
Study 28120127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25644589 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment during follow-up
Number of subjects: 467
Study 25644589 — intervention group
Group type: EXPERIMENTAL
Intervention: Income from sources other than sex work
Number of subjects: 467
Study 25644589 — intervention group
Group type: EXPERIMENTAL
Intervention: Police interactions
Number of subjects: 467
Study 25644589 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare access
Number of subjects: 467
Study 24702710 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted inactivated trivalent split-virion influenza vaccine (AS03-TIV)
Number of subjects: 595
Study 24702710 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (TIV)
Number of subjects: 595
Study 22348696 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1.2-mg SMV
Number of subjects: 72
Study 22348696 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 72
Study 19352587 — intervention group
Group type: EXPERIMENTAL
Intervention: GI + PP
Number of subjects: 76
Study 19352587 — intervention group
Group type: COMPARATOR
Intervention: GI
Number of subjects: 76
Study 18069280 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (SCT)
Number of subjects: 0
Study 18069280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem autologous SCT
Number of subjects: 0
Study 18069280 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous SCT followed by reduced-intensity conditioning allogeneic transplantation
Number of subjects: 0
Study 18069280 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs including thalidomide, lenalidomide, or bortezomib in combination with SCT
Number of subjects: 0
Study 15098135 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients (vitreo‐retinal surgery, brachytherapy, proton beam radiation)
Number of subjects: 140
Study 15098135 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 140
Study 17240934 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolly Brush
Number of subjects: 0
Study 10565800 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 10565800 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 30
Study 9308335 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for epilepsy
Number of subjects: 347
Study 1863725 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DA)
Number of subjects: 27
Study 1863725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 27
Study 6870066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator therapy (hydralazine or nifedipine) for Group I; nitroprusside followed by minoxidil or hydralazine for Group II.
Number of subjects: 35
Study 6870066 — intervention group
Group type: COMPARATOR
Intervention: Control right heart catheterization for both groups.
Number of subjects: 35
Study 31802198 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable collagen biomembrane
Number of subjects: 100
Study 31536935 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin-impregnated dog collars (4%)
Number of subjects: 1609
Study 31536935 — intervention group
Group type: COMPARATOR
Intervention: Control area (no intervention)
Number of subjects: 1609
Study 30372403 — intervention group
Group type: EXPERIMENTAL
Intervention: Research interest
Number of subjects: 26
Study 30372403 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-scientist decline and shortage
Number of subjects: 26
Study 30372403 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum issues
Number of subjects: 26
Study 30372403 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills (motivation and self-efficacy)
Number of subjects: 26
Study 30372403 — intervention group
Group type: EXPERIMENTAL
Intervention: Research needs
Number of subjects: 26
Study 30372403 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic and cultural issues
Number of subjects: 26
Study 26829094 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration training
Number of subjects: 45
Study 26829094 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration plus task-related training
Number of subjects: 45
Study 26829094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 24794451 — intervention group
Group type: EXPERIMENTAL
Intervention: IPP 20mmHg (P20 group)
Number of subjects: 67
Study 24794451 — intervention group
Group type: COMPARATOR
Intervention: IPP 12mmHg (P12 group)
Number of subjects: 67
Study 23146637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered titanium posts (TPs)
Number of subjects: 91
Study 23146637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered glass fiber-reinforced epoxy resin posts (GFREPs)
Number of subjects: 91
Study 23146637 — intervention group
Group type: COMPARATOR
Intervention: Both post materials (GFREPs and TPs)
Number of subjects: 91
Study 21029429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 600 mg thrice daily
Number of subjects: 17
Study 21029429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 18410211 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families Program (SAAF)
Number of subjects: 167
Study 18410211 — intervention group
Group type: COMPARATOR
Intervention: Control families
Number of subjects: 167
Study 15813357 — intervention group
Group type: COMPARATOR
Intervention: No treatment after the first seizure
Number of subjects: 30
Study 15813357 — intervention group
Group type: COMPARATOR
Intervention: Rectal diazepam at seizure onset
Number of subjects: 30
Study 12029546 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated myocardial perfusion tomography (gMPT)
Number of subjects: 37
Study 12029546 — intervention group
Group type: COMPARATOR
Intervention: Gated blood pool tomography (gBPT)
Number of subjects: 37
Study 10489005 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 135
Study 10489005 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 135
Study 10489005 — intervention group
Group type: COMPARATOR
Intervention: Control Treatment (CT)
Number of subjects: 135
Study 9545903 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (Dyract)
Number of subjects: 50
Study 9545903 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite (Pekafill)
Number of subjects: 50
Study 9545903 — intervention group
Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RM GIC) (Fuji II LC)
Number of subjects: 50
Study 1916649 — intervention group
Group type: EXPERIMENTAL
Intervention: met‐hGH (0.08 mg/kg desirable body weight)
Number of subjects: 12
Study 1916649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bacteriostatic water diluent)
Number of subjects: 12
Study 31792940 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRD screening using the Memory Impairment Screen or the Mini-Cog
Number of subjects: 4005
Study 31792940 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRD screening
Number of subjects: 4005
Study 31792940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ADRD screening)
Number of subjects: 4005
Study 31169794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 3 × 5 min occlusion 220 mm Hg/reperfusion 0 mm Hg, bilaterally on thighs
Number of subjects: 13
Study 31169794 — intervention group
Group type: COMPARATOR
Intervention: SHAM - 20 mm Hg
Number of subjects: 13
Study 31169794 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 13
Study 29245223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 60
Study 29245223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25228126 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of prednisone daily for 2 years
Number of subjects: 0
Study 23230115 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen (HN; CON plus urea supplement)
Number of subjects: 20
Study 23230115 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen and sulfur (HNS)
Number of subjects: 20
Study 23230115 — intervention group
Group type: COMPARATOR
Intervention: High sulfur (HS)
Number of subjects: 20
Study 23230115 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; 13.4% CP and 0.17% S)
Number of subjects: 20
Study 21261241 — intervention group
Group type: EXPERIMENTAL
Intervention: IO myectomy
Number of subjects: 50
Study 21261241 — intervention group
Group type: COMPARATOR
Intervention: IO recession
Number of subjects: 50
Study 19913145 — intervention group
Group type: EXPERIMENTAL
Intervention: ETG-releasing implant
Number of subjects: 40
Study 19913145 — intervention group
Group type: COMPARATOR
Intervention: DMPA
Number of subjects: 40
Study 16762627 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg daily
Number of subjects: 286
Study 16762627 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 286
Study 14973334 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion of the distal interphalangeal joints of individual fingers
Number of subjects: 8
Study 11722408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + Colistin (CIP + COL)
Number of subjects: 64
Study 11722408 — intervention group
Group type: COMPARATOR
Intervention: Neomycin + Colistin (NEO + COL)
Number of subjects: 64
Study 9137175 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laser nucleolysis with a carbon dioxide laser
Number of subjects: 50
Study 7956657 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep preparation
Number of subjects: 1000
Study 7956657 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap smear
Number of subjects: 1000
Study 3604619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU heparin and 0.5 mg dihydroergotamine injected subcutaneously twice daily
Number of subjects: 194
Study 3604619 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 194
Study 31286727 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue Sanfeng and Tiaohe Ganpi acupuncture
Number of subjects: 76
Study 31286727 — intervention group
Group type: COMPARATOR
Intervention: Nifedipin (Control)
Number of subjects: 76
Study 27545858 — intervention group
Group type: COMPARATOR
Intervention: NTP‐CE (new topical panthenol‐containing emollient)
Number of subjects: 109
Study 27545858 — intervention group
Group type: COMPARATOR
Intervention: Control areas
Number of subjects: 109
Study 25092537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Number of subjects: 3
Study 25092537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 23796707 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month multidisciplinary intervention
Number of subjects: 21
Study 21774708 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 331
Study 21774708 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 331
Study 19353407 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment (indapamide 1.5 mg sustained release +/‐2‐4 mg perindopril)
Number of subjects: 3845
Study 19353407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3845
Study 16310299 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive asymmetric lifts by novice handlers
Number of subjects: 24
Study 16310299 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive asymmetric lifts by experienced handlers
Number of subjects: 24
Study 16310299 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive asymmetric lifts at unaccustomed lift frequencies and weights
Number of subjects: 24
Study 12717213 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg per dose every 14 days for five doses (group I, n=107)
Number of subjects: 297
Study 12717213 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg per dose every 14 days for two doses (group II, n=112)
Number of subjects: 297
Study 12717213 — intervention group
Group type: COMPARATOR
Intervention: No antibody induction (group III, n=78)
Number of subjects: 297
Study 12717213 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg per dose every 14 days for five doses (group I)
Number of subjects: 297
Study 12717213 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg per dose every 14 days for two doses (group II)
Number of subjects: 297
Study 12717213 — intervention group
Group type: COMPARATOR
Intervention: No antibody induction (group III)
Number of subjects: 297
Study 11117873 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-044
Number of subjects: 420
Study 11117873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 9166992 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 9166992 — intervention group
Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 0
Study 8419001 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic 28-amino acid alpha-human ANP (0.1 micrograms/kg per minute)
Number of subjects: 14
Study 8419001 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 14
Study 3706427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state (50 gm, 1-hour plasma glucose screening test)
Number of subjects: 70
Study 3706427 — intervention group
Group type: COMPARATOR
Intervention: Fed state (50 gm, 1-hour plasma glucose screening test after a standard 600 kcal meal)
Number of subjects: 70
Study 3706427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state (50 gm, 1-hour plasma glucose screening test)
Number of subjects: 70
Study 30957487 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Sampling (SS)
Number of subjects: 10
Study 30957487 — intervention group
Group type: COMPARATOR
Intervention: Random Sampling (RS)
Number of subjects: 10
Study 30957487 — intervention group
Group type: COMPARATOR
Intervention: Line Sampling (LS)
Number of subjects: 10
Study 30957487 — intervention group
Group type: EXPERIMENTAL
Intervention: All sampling strategies (SS, RS, LS)
Number of subjects: 10
Study 28673328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized pedometer-based walking program with weekly step goals, behavioral face-to-face sessions with a physician, and regular telephone calls with a research nurse for 6 months.
Number of subjects: 200
Study 28673328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized pedometer-based walking program
Number of subjects: 200
Study 25879592 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV₁₅₀
Number of subjects: 16
Study 25879592 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA₁₅₀
Number of subjects: 16
Study 25879592 — intervention group
Group type: COMPARATOR
Intervention: PSV₁₅₀
Number of subjects: 16
Study 25879592 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV₁₀₀
Number of subjects: 16
Study 25879592 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA₁₀₀
Number of subjects: 16
Study 25879592 — intervention group
Group type: COMPARATOR
Intervention: PSV₁₀₀
Number of subjects: 16
Study 25879592 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV
Number of subjects: 16
Study 25879592 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 16
Study 25879592 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV and NAVA
Number of subjects: 16
Study 24286472 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of adalimumab (ADA)
Number of subjects: 50
Study 21931037 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 92
Study 21931037 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 92
Study 19186727 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint stimulating therapy
Number of subjects: 3697
Study 16426990 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 92
Study 16426990 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study 15086180 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy during colonoscopy, n=15
Number of subjects: 29
Study 15086180 — intervention group
Group type: COMPARATOR
Intervention: No music during colonoscopy, n=14
Number of subjects: 29
Study 15086180 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 29
Study 15086180 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 29
Study 11500289 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching by physical examination teaching associates (PETAs)
Number of subjects: 0
Study 11500289 — intervention group
Group type: COMPARATOR
Intervention: Traditional faculty‐taught course
Number of subjects: 0
Study 11500289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of using PETAs
Number of subjects: 0
Study 9731580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN) 3 MU three times a week starting within 2 weeks after transplantation for 1 year
Number of subjects: 86
Study 9731580 — intervention group
Group type: COMPARATOR
Intervention: Control (no IFN)
Number of subjects: 86
Study 9731580 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN)
Number of subjects: 86
Study 9731580 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA level > 100 x 10(5) Eq/mL at 1 month after transplantation
Number of subjects: 86
Study 7977894 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 62
Study 7977894 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 62
Study 2807006 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus twice-weekly cis-platinum (group III)
Number of subjects: 0
Study 2807006 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus weekly cis-platinum (group II)
Number of subjects: 0
Study 2807006 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (group I)
Number of subjects: 0
Study 2807006 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus cis-platinum (groups II and III)
Number of subjects: 0
Study 808849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile plastic‐tent isolators with laminar air flow (Life Islands) and whole-body decontamination
Number of subjects: 28
Study 808849 — intervention group
Group type: COMPARATOR
Intervention: Reverse isolation
Number of subjects: 28
Study 808849 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions in group A
Number of subjects: 28
Study 808849 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Islands for patients with agranulocytosis of varying origin (group C)
Number of subjects: 28
Study 29701041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with femoral nerve block
Number of subjects: 60
Study 26397982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryton dedicated side branch stent
Number of subjects: 289
Study 26397982 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 289
Study 26198562 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Connect system (telemonitoring and virtual provider appointments)
Number of subjects: 0